Exact Mass: 385.2617

Exact Mass Matches: 385.2617

Found 51 metabolites which its exact mass value is equals to given mass value 385.2617, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Actinonin

(2R)-N'-hydroxy-N-[(2S)-1-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]-2-pentylbutanediamide

C19H35N3O5 (385.2577)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents Actinonin ((-)-Actinonin) is a naturally occurring antibacterial agent produced by Actinomyces. Actinonin inhibits aminopeptidase M, aminopeptidase N and leucine aminopeptidase. Actinonin is a potent reversible peptide deformylase (PDF) inhibitor with a Ki of 0.28 nM. Actinonin also inhibits MMP-1, MMP-3, MMP-8, MMP-9, and hmeprin α with Ki values of 300 nM, 1,700 nM, 190 nM, 330 nM, and 20 nM, respectively. Actinonin is an apoptosis inducer. Actinonin has antiproliferative and antitumor activities[1][2][3][4][5].

   
   

N-Oleoyl Cysteine

2-[(1-Hydroxyoctadec-9-en-1-ylidene)amino]-3-sulphanylpropanoic acid

C21H39NO3S (385.2651)


N-oleoyl cysteine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Oleic acid amide of Cysteine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Oleoyl Cysteine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Oleoyl Cysteine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

N-Docosahexaenoyl Glycine

2-(docosa-4,7,10,13,16,19-hexaenamido)acetic acid

C24H35NO3 (385.2617)


N-docosahexaenoyl glycine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Glycine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl Glycine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl Glycine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

Actinonin

2-[(Dihydroxycarbonimidoyl)methyl]-N-{1-[2-(hydroxymethyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}heptanimidate

C19H35N3O5 (385.2577)


   

Temiverine

4-Diethylamino-1,1-dimethylbut-2-yn-1-yl-2-cyclohexyl-2-hydroxy-2-phenylacetate monohydrochloride monohydrate

C24H35NO3 (385.2617)


   

Methyl longistylumphylline B

Methyl longistylumphylline B

C24H35NO3 (385.2617)


   
   

Jynosine

Denudatine 15-acetate

C24H35NO3 (385.2617)


   

N-Docosa-4,7,10,13,16,19-hexaenoylglycine

N-Docosa-4,7,10,13,16,19-hexaenoylglycine

C24H35NO3 (385.2617)


   

4,5-dihydroguineensine|piperchabamide D

4,5-dihydroguineensine|piperchabamide D

C24H35NO3 (385.2617)


   
   

aspochalasin R

aspochalasin R

C24H35NO3 (385.2617)


   

(3R*,4S*,5S*,6S*,8R*,10R*)-3-[1,2,4a,5,6,7,8,8a-octahydro-3,6,8-trimethyl-2-[(E)-1-methyl-1-propenyl]-1-naphthalenyl]carbonyl-1,5-dihydro-5-methoxy-5-methyl-2H-pyrrol-2-one|ascosalipyrrolidinone B

(3R*,4S*,5S*,6S*,8R*,10R*)-3-[1,2,4a,5,6,7,8,8a-octahydro-3,6,8-trimethyl-2-[(E)-1-methyl-1-propenyl]-1-naphthalenyl]carbonyl-1,5-dihydro-5-methoxy-5-methyl-2H-pyrrol-2-one|ascosalipyrrolidinone B

C24H35NO3 (385.2617)


   

MLS002153199-01!Actinonin13434-13-4

MLS002153199-01!Actinonin13434-13-4

C19H35N3O5 (385.2577)


   

Docosahexaenoyl Glycine

N-(1-oxo-4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenyl)-glycine

C24H35NO3 (385.2617)


   

Brilliant Green cation

Brilliant Green cation

C27H33N2+ (385.2644)


   

Temiverine

Temiverine

C24H35NO3 (385.2617)


D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators

   

Glycine, N-(1-oxo-4,7,10,13,16,19-docosahexaenyl)-(9CI)

Glycine, N-(1-oxo-4,7,10,13,16,19-docosahexaenyl)-(9CI)

C24H35NO3 (385.2617)


   

N-Oleoyl Cysteine

N-Oleoyl Cysteine

C21H39NO3S (385.2651)


   

1-ethyl-2-[3-(1-ethyl-3,3-dimethyl-1,3-dihydro-2H-indol-2-ylidene)prop-1-en-1-yl]-3,3-dimethyl-3H-indolium

1-ethyl-2-[3-(1-ethyl-3,3-dimethyl-1,3-dihydro-2H-indol-2-ylidene)prop-1-en-1-yl]-3,3-dimethyl-3H-indolium

C27H33N2+ (385.2644)


   

Docosahexaenoylglycine

Docosahexaenoylglycine

C24H35NO3 (385.2617)


   

Hoffmans violet free base

Hoffmans violet free base

C26H31N3 (385.2518)


   

C3-indocyanine cation

C3-indocyanine cation

C27H33N2+ (385.2644)


   

(2E)-15-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]pentadec-2-enoate

(2E)-15-[(3,6-dideoxy-alpha-L-arabino-hexopyranosyl)oxy]pentadec-2-enoate

C21H37O6- (385.259)


   

(E,14R)-14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxypentadec-2-enoate

(E,14R)-14-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxypentadec-2-enoate

C21H37O6- (385.259)


   
   

ascr#25(1-)

ascr#25(1-)

C21H37O6 (385.259)


Conjugate base of ascr#25

   

oscr#25(1-)

oscr#25(1-)

C21H37O6 (385.259)


A hydroxy fatty acid ascaroside anion that is the conjugate base of oscr#25, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

NA-Cys 18:1(9Z)

NA-Cys 18:1(9Z)

C21H39NO3S (385.2651)


   

NA-Gly 22:6(4Z,7Z,10Z,13Z,16Z,19Z)

NA-Gly 22:6(4Z,7Z,10Z,13Z,16Z,19Z)

C24H35NO3 (385.2617)


   

NA-Met 16:1(9Z)

NA-Met 16:1(9Z)

C21H39NO3S (385.2651)


   

NA-PABA 17:2(9Z,12Z)

NA-PABA 17:2(9Z,12Z)

C24H35NO3 (385.2617)


   

3-[2-(but-2-en-2-yl)-3,6,8-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl]-5-methoxy-5-methylpyrrol-2-ol

3-[2-(but-2-en-2-yl)-3,6,8-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl]-5-methoxy-5-methylpyrrol-2-ol

C24H35NO3 (385.2617)


   

(3s,3ar,4s,6as,15ar)-1,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one

(3s,3ar,4s,6as,15ar)-1,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one

C24H35NO3 (385.2617)


   

(2r)-2-[(dihydroxycarbonimidoyl)methyl]-n-[(2s)-1-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]heptanimidic acid

(2r)-2-[(dihydroxycarbonimidoyl)methyl]-n-[(2s)-1-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]heptanimidic acid

C19H35N3O5 (385.2577)


   

(5r)-3-[(1s,2r,4ar,6r,8s,8as)-2-[(2e)-but-2-en-2-yl]-3,6,8-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl]-5-methoxy-5-methylpyrrol-2-ol

(5r)-3-[(1s,2r,4ar,6r,8s,8as)-2-[(2e)-but-2-en-2-yl]-3,6,8-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl]-5-methoxy-5-methylpyrrol-2-ol

C24H35NO3 (385.2617)


   

13-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)trideca-2,12-dienimidic acid

13-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)trideca-2,12-dienimidic acid

C24H35NO3 (385.2617)


   

2-[(2e,5e,7e,11e)-10-hydroxy-3,7,9,11-tetramethyltrideca-2,5,7,11-tetraen-1-yl]-6-methoxy-3-methylpyridin-4-ol

2-[(2e,5e,7e,11e)-10-hydroxy-3,7,9,11-tetramethyltrideca-2,5,7,11-tetraen-1-yl]-6-methoxy-3-methylpyridin-4-ol

C24H35NO3 (385.2617)


   

(3s,3ar,4s,6as,12s,15ar)-1,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one

(3s,3ar,4s,6as,12s,15ar)-1,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one

C24H35NO3 (385.2617)


   

1,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one

1,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one

C24H35NO3 (385.2617)


   

1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione

1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione

C24H35NO3 (385.2617)


   

(3s,3ar,4s,6as,12r,15ar)-1,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one

(3s,3ar,4s,6as,12r,15ar)-1,12-dihydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,12h-cycloundeca[d]isoindol-15-one

C24H35NO3 (385.2617)


   

(1s,2s,5r,7r,8r,11r,12s,18r)-12-methyl-6-methylidene-17-oxa-14-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]docosan-7-yl acetate

(1s,2s,5r,7r,8r,11r,12s,18r)-12-methyl-6-methylidene-17-oxa-14-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]docosan-7-yl acetate

C24H35NO3 (385.2617)


   

3-[(1s,2r,4ar,6r,8s,8as)-2-[(2e)-but-2-en-2-yl]-3,6,8-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl]-5-methoxy-5-methylpyrrol-2-ol

3-[(1s,2r,4ar,6r,8s,8as)-2-[(2e)-but-2-en-2-yl]-3,6,8-trimethyl-1,2,4a,5,6,7,8,8a-octahydronaphthalene-1-carbonyl]-5-methoxy-5-methylpyrrol-2-ol

C24H35NO3 (385.2617)


   

methyl (1'r,3s,5's,11'r,12'r)-6-isopropyl-3'-methyl-2,4-dihydro-3'-azaspiro[pyran-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

methyl (1'r,3s,5's,11'r,12'r)-6-isopropyl-3'-methyl-2,4-dihydro-3'-azaspiro[pyran-3,15'-tetracyclo[6.5.1.1¹,⁵.0¹¹,¹⁴]pentadecan]-8'(14')-ene-12'-carboxylate

C24H35NO3 (385.2617)


   

(3s,3ar,4s,6as,15ar)-1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione

(3s,3ar,4s,6as,15ar)-1-hydroxy-4,5,8-trimethyl-3-(2-methylpropyl)-3h,3ah,4h,6ah,9h,10h,11h,13h,14h-cycloundeca[d]isoindole-12,15-dione

C24H35NO3 (385.2617)


   

(2e,12e)-13-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)trideca-2,12-dienimidic acid

(2e,12e)-13-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)trideca-2,12-dienimidic acid

C24H35NO3 (385.2617)


   

12-methyl-6-methylidene-17-oxa-14-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]docosan-7-yl acetate

12-methyl-6-methylidene-17-oxa-14-azahexacyclo[10.6.3.1⁵,⁸.0¹,¹¹.0²,⁸.0¹⁴,¹⁸]docosan-7-yl acetate

C24H35NO3 (385.2617)